Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Intractable Hiccup and Nausea With Pariaqueductal Lesions in Neuromyelitis Optica
Neurol 65:1479-1482, Misu,T.,et al, 2005
Diffusion MRI in Multiple Sclerosis
Neurol 65:1526-1532, Rovaris,M.,et al, 2005
Axonal Injury in Early Multiple Sclerosis is Irreversible and Independent of the Short-Term Disease Evolution
Neurol 65:1626-1630, Rovaris,M.,et al, 2005
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
Unusual Presentation of Central Nervous System Cryptococcal Infection in an Immunocompetent Patient
AJNR 26:2522-2526, Saigal,G.,et al, 2005
Chasing "Chasing the Dragon" with MRI: Leukoencephalopathy in Drug Abuse
Br J Radiol 78:997-1004, Bartlett,E. &Mikulis,D.J., 2005
The Ependymal "Dot-Dash" Sign: An MR Imaging Finding of Early Multiple Sclerosis
AJNR 26:2033-2036, Lisanti, C.J.,et al, 2005
Neurologic and Developmental Disability at Six Years of Age After Extremely Preterm Birth
NEJM 352:9-19, 71, Marlow,N.,et al, 2005
Is Optic Neuritis More Benign Than Other First Attacks in Multiple Sclerosis?
Ann Neurol 57:210-215, Tintore, M., et al, 2005
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Identification of Embolic Stroke Patterns by Diffusion-Weighted MRI in Clinically Defined Lacunar Stroke Syndromes
Stroke 36:757-761, Wessels,T.,et al, 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005
Anti-a4 Integrin Therapy for Multiple Sclerosis
Neurol 64:1336-1342, Rice,G.P.A.,et al, 2005
Mechanisms of Bihemispheric Brain Infarctions in the Anterior Circulation on Diffusion-Weighted Images
AJNR 26:809-814, Saito,K.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Triaging Transient Ischemic Attack and Minor Stroke Patients Using Acute Magnetic Resonance Imaging
Ann Neurol 57:848-854, Coutts,S.B.,et al, 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Vagal Nerve Stimulation Effect on Cerebellar Tremor in Multiple Sclerosis
Neurol 65:499, Marrosu,F.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Oligodendroglioma and Multiple Sclerosis. A Case Report.
Neurocirugia (Astur) 15:378-83, de la lama,A.,et al, 2004
Multiple Sclerosis and Gliomas. Clinical Remarks on 10 Cases and Critical Review of the Literature.
J Neurosurg Sci 48:129-33, Isadori,A.,et al, 2004
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Treatment of Trigeminal Neuralgia Associated with Multiple Sclerosis
Neurol 63:1714-1715, Rasche,D.,et al, 2004
Clinical Characteristics of African Americans vs Caucasian Americans with Multiple Sclerosis
Neurol 63:2039-2045, Bree,B.A.C.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
A Serum Autoantibody Marker of Neuromyelitis Optica: Distinction from Multiple Sclerosis
Lancet 364:2106-2112, Lennon,V.A.,et al, 2004
Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004
The Bioavailability of IV Methylprednisolone and Oral Prednisone in Multiple Sclerosis
Neurol 63:1079-1080, Morrow,S.A.,et al, 2004
Donepezil Improved Memory in Multiple Sclerosis in a Randomized Clinical Trial
Neurol 63:1579-1585, Krupp,L.B.,et al, 2004
The Neurological and Cognitive Sequelae of Cardiac Arrest
Neurol 63:1774-1778, Lim,C.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
Clinical and MRI Outcome after Autologous Hematoipoietic Stem Cell Transplantation in MS
Neurol 62:282-284,168, Saiz,A.,et al, 2004
The MRI Appearance of Tumefactive Demyelinating Lesions
AJR 182:195-199, Given II,C.A.,et al, 2004
Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes
Arch Neurol 61:222-224, Sastre-Garriga,J.,et al, 2004
Infratentorial Lesions Predict Long-term Disability in Patients with Initial Findings Suggestive of Multiple Sclerosis
Arch Neurol 61:217-221, Minneboo,A.,et al, 2004
Early Risk of Recurrence by Subtype of Ischemic Stroke in Population-Based Incidence Studies
Neurol 62:569-573, Lovett,J.K.,et al, 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Susac Syndrome:Report of Four Cases and Review of the Literature
AJNR 25:382-388,351, Do,T.H.,et al, 2004
Acute Aphasia in Multiple Sclerosis, A Multicenter Study of 22 Patients
Neurol 62:974-977, Lacour,A.,et al, 2004
Fibromuscular Dysplasia
NEJM 350:1862-1871, Slovut,D.P. &Olin,J.W., 2004